Please assess the completion status of the following clinical trial:

Trial Title: RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject (or Legal Guardian) is willing and able to provide consent before any study-specific tests or procedures are performed and agree to attend all required follow-up visits;~2. Subject at least 20 years of age;~3. Chronic symptomatic lower limb ischemia defined as Rutherford classification 2, 3, or 4;~4. Target lesion is in the native SFA and/or PPA down to the P1 segment;~5. Patent popliteal and infrapopliteal arteries, i.e., single vessel runoff or better with at least one of three vessels patent (less than 50 % stenosis) to the ankle or foot;~6. Reference vessel diameter ≥ 4 mm and ≤ 8 mm by visual estimate;~7. Angiographic evidence that target lesion consists of a single de novo, non-stented and non-atherectomy treated or restenotic lesion (or tandem lesions or a combination lesion as defined below) that is:~   * ≥ 70%-99% stenotic with total lesion length up to 180 mm by visual estimate.~  * Occluded with total lesion length ≤ 100 mm by visual estimate.~  * If lesion is restenotic, most recent PTA treatment must be \> 3 months prior to enrollment.~Exclusion Criteria:~1. Life expectancy, documented in the Investigator's opinion, of less than 12 months;~2. Hemorrhagic stroke or cardiac event (e.g. STEMI, unstable angina) within 6 months prior to enrollment;~3. Known allergies or sensitivities to heparin, aspirin, other anticoagulant/antiplatelet therapies, and/or paclitaxel;~4. Known hypersensitivity or contraindication to contrast dye that, in the opinion of the investigator, cannot be adequately pre-medicated;~5. Chronic renal insufficiency with serum creatinine \> 2.0 mg/dL within 30 days of index procedure or treatment with dialysis;~6. Platelet count \< 80,000 mm 3 or \> 600,000 mm 3 or history of bleeding diathesis;~7. Receiving immunosuppressive therapy;~8. Septicemia at the time of enrollment;~9. Any major intervention planned within 30 days post index procedure;~10. Presence of other hemodynamically significant outflow lesions in the target limb requiring intervention within 30 days of enrollment;~11. Failure to successfully cross the target lesion with a guidewire;~12. Failure to successfully pre-dilate the target vessel;~13. Patient has lesion that requires the use of adjunctive primary treatment modalities (i.e. laser, atherectomy, scoring/cutting balloon, other debulking devices, etc.) during the index procedure;~14. History of major amputation in the target limb;~15. Target lesion or vessel has ever been previously treated with stent (e.g. in-stent restenosis) or surgery. Target lesion or vessel has been treated with atherectomy or a DCB in the past 12 months;~16. Pregnant or breast feeding;~17. Presence of aneurysm in the target vessel;~18. Acute ischemia and/or acute thrombosis of the SFA/PPA prior to enrollment;~19. Patient has significant inflow disease which cannot be treated prior to the target lesion treatment;~20. Patient has perforated targeted vessel as evidenced by extravasation of contrast media;~21. Patient has severe calcification that renders the lesion undilatable;~22. Current participation in another investigational drug or device clinical trial that has not completed the primary endpoint at the time of randomization/enrollment or that clinically interferes with the current trial endpoints.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RANGER™ Paclitaxel Coated Balloon (Type: EXPERIMENTAL): RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the SFA/PPA at the index procedure.~Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.
- Standard Balloon Angioplasty (Type: ACTIVE_COMPARATOR): Standard Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.

Based on this trial design, predict the completion outcome and termination type (if applicable).